Unum Therapeutics Inc.
200 CambridgePark Drive, Suite 3100
Cambridge, Massachusetts 02140
April 29, 2019
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Unum Therapeutics Inc.: Registration Statement on Form S-3 filed April 2, 2019 (File No. 333-230678) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Unum Therapeutics Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to May 1, 2019, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact Danielle Lauzon of Goodwin Procter LLP at (617) 570-1955.
| Sincerely, |
| Unum Therapeutics Inc. |
| /s/ Charles Wilson |
| Charles Wilson, Ph.D. |
| Chief Executive Officer and President |
| cc: | John Green, Unum Therapeutics Inc. |
Kingsley L. Taft, Esq., Goodwin Procter LLP
Danielle Lauzon, Esq., Goodwin Procter LLP